MedTrace Logo

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

NCT04165993 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2023-09-21

No results posted yet for this study

Summary

This is an open-label, three-cohort phase 2 study of KN026 in subjects with advanced breast Cancer.

Conditions

Interventions

DRUG

Concurrent chemotherapy and KN026

30 mg/kg Q3W KN026 75 mg/m2 docetaxol

DRUG

KN026 monotherapy

30 mg/kg Q3W KN026

DRUG

KN026 combination

30 mg/kg Q3W KN026 5 mg/kg Q3W KN046

Sponsors & Collaborators

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Qingyuan Zhang, Professor · The Second Affiliated Hospital of Harbin Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2021-05-27
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165993 on ClinicalTrials.gov